Hemoglobin Decline in Chemotherapy Patients Prior to and after Policy Changes Affecting Use of Erythropoiesisstimulating Agents: 2006 - 2009

Journal of International Medical Research

Volumn 40, Issue 4, 2012, Pages 1532-1545

  Hill, J W ^a   Cong, Z ^b   Hess, G ^a,c,d   Mcgarvey, N ^e   Nordyke, R J ^f  

^a IQVIA   (United States)

^b AMGEN INC   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f PriceSpective   (United States)

Author keywords

Anemia; Cancer; Concomitant administration; Erythropoiesis stimulating agents; Hemoglobin; Myelosuppressive chemotherapy; Us practice guidelines

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; ELECTRONIC MEDICAL RECORD; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS;

EID: 84867529506     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/147323001204000433     Document Type: Review

References (35)

1. Bohlius J, Schmidlin K, Brillant C, et al Erythropoietin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 3: CD007303.
2. Seidenfeld J, Piper M, Bohlius J, et al Comparative effectiveness of epoetin and darbepoetin for managing anemia in patients undergoing cancer treatment. AHRQ Comp Effect Rev 2006 ( available at: http://effectivehealthcare. ahrq.gov/repFiles/EP O%20Final.pdf).
3. Balducci L: Anemia, cancer, and aging. Cancer Control 2003; 10: 478 - 486.
4. Bron D, Meuleman N, Mascaux C: Biological basis of anemia. Semin Oncol 2001; 28( 2 suppl 8): 1 - 6.
5. Caro JJ, Salas M, Ward A, et al Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91: 2214 - 2221.
6. Cella D: Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25( 3 suppl 7): 43 - 46.
7. Cella D, Dobrez D, Glaspy J: Control of cancerrelated anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol 2003; 14: 511 -519.
8. Curt GA, Breitbart W, Cella D, et al. Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000; 5: 353 - 360.
9. Berndt E, Kallich J, McDermott A, et al Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005; 23: 505 - 514.
10. Berndt E, Crown W, Kallich J, et al The impact of anaemia and its treatment on employee disability and medical costs. Pharmacoeconomics 2005; 23: 183 - 192.
11. Henry DH, Viswanathan HN, Elkin EP, et al Symptoms and treatment burden associated with cancer treatment: results from a crosssectional national survey in the U.S. Support Care Cancer 2008; 16: 791 - 801.
12. Lyman GH, Berndt ER, Kallich JD, et al The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005; 8: 149-156. (Pubitemid 40525376)
13. National Comprehensive Cancer Network (NCCN): NCCN Updates: Cancer- and Treatment-related Anemia Guidelines, December 20, 2007; Fort Washington: NCCN (available at: http://www.nccn.org/about/ news/newsinfo.asp?NewsID= 125).
14. Aapro MS, Link H: September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008; 13( suppl 3): 33 - 36.
15. Mikhael J, Melosky B, Cripps C, et al Canadian supportive care recommendations for the management of anemia in patients with cancer. Curr Oncol 2007; 14: 209 - 217.
16. Rizzo JD, Brouwers M, Hurley P, et al American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116: 4045 - 4059.
17. Koeller JM: Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18: 156 - 169.
18. Ludwig H, Fritz E: Anemia in cancer patients. Semin Oncol 1998; 25(3 suppl 7): 2-6. (Pubitemid 28326216)
19. Barrett-Lee PJ, Bailey NP, O'Brien ME, et al Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. Br J Cancer 2000; 82: 93 - 97.
20. Cremieux PY, Finkelstein SN, Berndt ER, et al Cost effectiveness, quality-adjusted life-years and supportive care: recombinant human erythropoietin as a treatment of cancerassociated anaemia. Pharmacoeconomics 1999; 16: 459 - 472.
21. Estrin JT, Schocket L, Kregenow R, et al A retrospective review of blood transfusions in cancer patients with anemia. Oncologist 1999; 4: 318 - 324.
22. Lehoczky O, Pulay T: Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer. Orv Hetil 2007; 148: 2133 - 2137 in Hungarian, English abstract].
23. Norum J, Moen M A: Practice and costs of red blood cell (RBC) transfusion in an oncological unit. Anticancer Res 2008; 28: 459 - 464.
24. Ueno W, Beveridge RA, Kales AN: Costs of outpatient red blood cell transfusions. J Support Oncol 2006; 4: 494 - 495.
25. Glaspy JA, Jadeja JS, Justice G, et al Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87: 268 - 276.
26. Hedenus M, Adriansson M, San Miguel J, et al Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122: 394 - 403.
27. Kotasek D, Steger G, Faught W, et al Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39: 2026 - 2034.
28. Vansteenkiste J, Pirker R, Massuti B, et al Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002; 94: 1211 - 1220.
29. Henke M, Laszig R, Rübe C, et al Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255 - 1260.
30. Leyland-Jones B, Semiglazov V, Pawlicki M, et al Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving firstline chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960 - 5972.
31. Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007; 25: 1027 - 1032.
32. Centers for Medicare and Medicaid Services: Decision Memo for Erythropoiesis Stimulating Agents (ESAs) for Non-renal Disease Indications (CAG-00383N) ( available at: http://www.cms. gov/medicare-coverage-database/ details/ncadecision-memo.aspx?NCAId=203&ver=16& NcaName= Erythropoiesis+Stimulating+Agents +(ESAs)+for+non-renal+disease+indications &DocID=CAG-00383N&bc=gAAAAAgAIAAA&).
33. National Institutes of Health: Aranesp (Darbepoetin Alfa) for Injection. Amgen, 2008 ( available at: http://nccs-dailymed.nlm.nih. gov/dailymed/archives/ fdaDrugInfo.cftn?archive id=16767).
34. Rim H: Chemotherapy-induced anemia in cancer patients. Oncolink ( available at: ( http://www.oncolink.org/resources/article.ctm? c=16&s=46&ss=205&id=1009).
35. Greer JP, Foerster J, Rodgers CM, et al Wintrobe's Clinical Hematology, 12th edn. Philadelphia: Lippincott Williams and Wilkins, 2008; p 3232.